Here, using ID8 murine ovarian cancer model, we show that combined anti-PD-1/OX40 mAb treatment significantly suppressed the 10 days established peritoneal ID8 tumor growth, resulting in 60% of treated mice tumor free 90 days after tumor injection. This evidence concerns the gene TNFRSF4 and ovarian cancer.